Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics已爲其第1/2階段研究的第一位患者注射了Bria-OTS,該研究旨在評估Briacell個性化下一代免疫療法的安全性和有效性
The study will investigate Bria-OTS alone and in combination with immune check point inhibitor tislelizumab (manufactured and supplied by BeiGene) for the treatment of metastatic breast cancer.
該研究將研究Bria-OTS單獨使用及與免疫檢查點抑制劑tislelizumab(由百濟神州製造和供應)聯用治療轉移性乳腺癌。
Bria-OTS is an enhanced form of Bria-IMT, currently in pivotal Phase 3 study for metastatic breast cancer.
Bria-OTS是Bria-IMt的增強形式,目前正處於轉移性乳腺癌的關鍵第三階段研究中。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。